Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 341

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 341
---
, the Company may also be obligated to pay Orega Biotech up to € 47

Avdoralimab (IPH5401) (anti-C5aR) rights acquired from Novo Nordisk A/S

At the agreement inception, an upfront payment of € 40 1.0 No

According to the agreement, the Company will pay additional payments according to the reach of specific steps. As of December 31, 2024, according to the uncertainty of these potential future payments, no

Development costs incurred by the Company are recognized as research and development expenses.

During 2022 fourth quarter, the Company was informed by the sponsor of the Phase 2 clinical trial evaluating avdoralimab in inflammation in bullous pemphigoid ("BP") indication of its decision to discontinue said trial. Consequently, the Company decided in December 2022 to stop the development of avdoralimab in bullous pemphigoid ("BP") indication in inflammation, only indication supporting the recoverable amount of the asset as of December 31, 2021 (as well that as of June 30, 2022).

Following that decision, the Company applied IAS 36 "Impairment of assets" and assessed that there was an indication of impairment sufficiently significant to result in the full impairment of the intangible asset. This depreciation was recognized with regard to the estimate of the recoverable value of avdoralimab's intangible assets, based on expected future cash flows, as of December 2022, date of the decision. Thus, on decision date to stop the development of avdoralimab in bullous pemphigoid ("BP") indication in inflammation, avdoralimab rights were fully written down to their net book value, i. e € 41,000

7)Property and equipment

  (in thousands of euro)      Land and buildings                 Laboratory equipment and other                 In progress         Total              
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  January 1, 2022                                     4,981                                          5,187      6                              10,174  
  Acquisitions                20                                                            535                 —                     555              
  Disposals                   —                                                           ( 11)                 ( 6)                ( 17)              
  Transfers                   —                                                               —                 —                       —              
  Depreciation                ( 759)                                                   (